title: The imperative for disease modifying treatments in Alzheimer's disease.
authors.forename: D
authors.initials: D
authors.lastname: Gallagher
authors.forename: A Ni
authors.initials: AN
authors.lastname: Mhaolain
authors.forename: B
authors.initials: B
authors.lastname: Lawlor
mesh_terms: D000544:Alzheimer Disease / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D016229:Amyloid beta-Peptides / Q000187:drug effects / Q000276:immunology*; D018450:Disease Progression; D038341:Glycogen Synthase Kinases / Q000037:antagonists & inhibitors; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007167:Immunotherapy; D007494:Ireland / Q000453:epidemiology; D012307:Risk Factors
chemical_list: D016229:Amyloid beta-Peptides; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D038341:Glycogen Synthase Kinases